Liminal BioSciences (LMNL:TSX) Investor Relations Material

Overview

Liminal BioSciences Inc., a biopharmaceutical company in its developmental stages, has set its sights on novel treatments for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. Its highly anticipated LMNL6511, a selective antagonist for the G-protein coupled receptor 84, is slated to commence a Phase 1 clinical trial. The company is also conducting preclinical research on OXER1 antagonists and GPR40 agonists. Formerly known as Prometic Life Sciences Inc., Liminal BioSciences Inc. announced its name-change in October 2019. Founded in 1994, the company is headquartered in Laval, Canada.

Annual Reports

Frequently Asked Questions

What is Liminal BioSciences's ticker?

Liminal BioSciences's ticker is LMNL

What exchange is Liminal BioSciences traded on?

The company's shares trade on the TSX stock exchange

Where are Liminal BioSciences's headquarters?

They are based in Laval, Quebec

How many employees does Liminal BioSciences have?

There are 201-500 employees working at Liminal BioSciences

What is Liminal BioSciences's website?

It is liminalbiosciences.com

What type of sector is Liminal BioSciences?

Liminal BioSciences is in the Healthcare sector

What type of industry is Liminal BioSciences?

Liminal BioSciences is in the Biotechnology industry

Who are Liminal BioSciences's peers and competitors?

The following five companies are Liminal BioSciences's industry peers:

- HUTCHMED (China)

- Ocular Therapeutix

- Catalyst Biosciences, Inc.

- Evofem Biosciences

- Ultragenyx Pharmaceutical